Evidence Explorer / Evidence record
NUTRIENTS & SUPPLEMENTS
Acetyl-L-carnitine for taxane neuropathy
Harm signal
Acetyl-L-carnitine did not prevent neuropathy at the primary time point and was associated with worse neuropathy later.
MS-N001 · Sources checked October 11, 2026 · Neuropathy prevention
What was studied?
People and setting: Women receiving adjuvant taxane chemotherapy for breast cancer
Evidence basis: Randomized double-blind trial; 409 evaluable participants
What can we conclude?
A biologically plausible supplement can fail—and cause harm—in a controlled trial. Findings are specific to this prevention setting.
Safety and practical context
Do not use it to prevent taxane neuropathy without discussing this harm signal with the oncology team.
Questions for the care team
- Does this evidence apply to my cancer, treatment and goal?
- Does the exact preparation or delivery method match the study?
- What benefit is plausible, what could go wrong, and what care must continue?
Sources
Connected reviews
Learn how to judge a study · Return to the evidence map
This is a concise evidence brief, not an exhaustive systematic review or a personal treatment recommendation. Evidence labels describe the named use; they are not formal GRADE ratings. A missing harm report does not establish safety.
